长药控股(300391) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥136,792,880.94, a decrease of 74.92% compared to ¥545,403,773.14 in the same period last year[5] - The net profit attributable to shareholders was -¥22,958,141.64, representing a decline of 256.75% from a profit of ¥14,645,911.14 in the previous year[5] - Total operating revenue for the current period is $136.79 million, a decrease of 75.1% compared to $545.40 million in the previous period[17] - Operating profit for the current period is a loss of $31.87 million, compared to a profit of $51.54 million in the previous period[18] - Net profit for the current period is a loss of $30.81 million, significantly lower than the profit of $50.23 million in the previous period[18] - Basic and diluted earnings per share for the current period are both -$0.0655, compared to $0.0418 in the previous period[18] Cash Flow - The net cash flow from operating activities was ¥24,341,147.26, an increase of 158.18% compared to -¥41,839,544.89 in the same period last year[5] - Cash flow from operating activities shows a net inflow of $24.34 million, contrasting with a net outflow of $41.84 million in the previous period[21] - The cash flow from financing activities showed a net outflow of -¥32,243,798.34, a decline of 116.61% compared to a net inflow of ¥194,088,746.52 in the previous year[8] - The company reported a net cash outflow from financing activities of $32.24 million, compared to an inflow of $194.09 million in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,668,309,118.72, reflecting a 2.51% increase from ¥3,578,587,920.62 at the end of the previous year[5] - The company's current assets totaled CNY 1,843,486,887.61, up from CNY 1,741,651,648.89 at the start of the year, indicating a growth of approximately 5.9%[14] - The total liabilities increased to CNY 2,034,501,520.14 from CNY 1,913,967,101.32, reflecting a rise of about 6.3%[15] - The company's cash and cash equivalents decreased to CNY 12,628,606.41 from CNY 17,474,790.79, representing a decline of approximately 27.5%[14] - The total non-current liabilities rose to CNY 390,477,474.99 from CNY 368,916,000.79, reflecting an increase of about 5.8%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,545, with no preferred shareholders[10] - The total equity attributable to the owners of the parent company decreased to CNY 777,714,584.27 from CNY 800,672,725.91, a decline of about 2.9%[15] Research and Development - Research and development expenses decreased by 75.35% to ¥2,011,134.43 from ¥8,157,597.25 in the previous year, attributed to the absence of the internal combustion engine segment[8] Inventory and Receivables - Accounts receivable stood at CNY 1,413,212,332.63, slightly down from CNY 1,428,970,534.49, showing a decrease of about 1.1%[14] - Inventory increased to CNY 71,590,247.89 from CNY 59,473,798.20, marking an increase of approximately 20.3%[14] Sales Performance - The company received $162.19 million in cash from sales of goods and services, a decrease from $480.15 million in the previous period[21] - Total operating costs for the current period are $161.38 million, down from $482.57 million, reflecting a reduction of 66.6%[17]